PLX

Protalix BioTherapeutics, Inc. Common Stock

2.72

USD

-0.03

-1.09%

Sep 25, 15:59 UTC -4

Closed

After-Market

2.71

-0.01

-0.18%

Protalix BioTherapeutics, Inc. Common Stock Profile

About

Protalix BioTherapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of recombinant therapeutic proteins. The company's product pipeline includes ProCellEx(R). Protalix BioTherapeutics Inc. is based in CARMIEL, Israel.

Info & Links

CEO

Dror Bashan

Headquarters

2 UNIVERSITY PLAZA, SUITE 100
HACKENSACK, NJ 07601, UNITED STATES

Auditor

Kesselman & Kesselman

Share holders

Employees

226

Protalix BioTherapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

218.75M

Enterprise Value

191.33M

Enterprise Value/EBITDA(ttm)

7.70

Price to Earnings Ratio(ttm)

11.96

Price to Sales(ttm)

2.75

Price to Book(mrq)

3.10

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

62.87%

Operating Margin(ttm)

23.50%

Profit Margin(ttm)

6.53%

Return on Equity(ttm)

31.60%

Return on Invested Capital(ttm)

25.57%

Return on Assets(ttm)

20.09%

Income Statement

Revenue(ttm)

80.62M

Revenue Per Share(ttm)

1.00

Gross Profit(ttm)

55.79M

EBITDA(ttm)³

24.86M

Net Income Available to Common(ttm)

18.95M

Diluted EPS(ttm)

0.23

Share Statistics

Beta (5Y Monthly)

0.02

52-Week Change

32.04%

S&P 500 52-Week Change

19.38%

S&P 500 Member

Stock Optionable

Yes

Total Shares Outstanding¹

80.57M

Dividend Yield

0.00%

Float⁴

75.17M

% Held by Insiders

6.70%

% Held by Institutions

16.53%

Balance Sheet

Total Cash(mrq)

41.38M

Total Cash Per Share(mrq)

0.51

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

2.94%

Quick Ratio(mrq)

1.91%

Book Value Per Share(mrq)

0.89

Cash Flow

Operating Cash Flow Per Share(ytd)

0.14

Free Cash Flow(ytd)

10.27M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

PLX